These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 74729)

  • 21. [Use of specific angiotensin inhibitors in the diagnosis and treatment of arterial hypertension].
    Novikova LS; Arabidze GG
    Ter Arkh; 1979; 51(5):99-108. PubMed ID: 222004
    [No Abstract]   [Full Text] [Related]  

  • 22. [Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].
    Beyer J; Liebau G; Steiner B; Hayduk K
    Klin Wochenschr; 1978 Sep; 56(17):859-64. PubMed ID: 713415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of saralasin on normal blood pressure and on reno-vascular hypertension (author's transl)].
    Beckerhoff R; Vetter W; Furrer J; Nussberger J; Schmied U; Siegenthaler W
    Dtsch Med Wochenschr; 1976 Mar; 101(11):398-401. PubMed ID: 1253700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypotensive action of captopril and saralasin in intact and anephric spontaneously hypertensive rats.
    Hutchinson JS; Mendelsohn FA; Doyle AE
    Hypertension; 1980; 2(2):119-24. PubMed ID: 6991407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Converting enzyme inhibitor and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor.
    Thurston H; Swales JD
    Circ Res; 1978 May; 42(5):588-92. PubMed ID: 639180
    [No Abstract]   [Full Text] [Related]  

  • 26. Time course of changes in plasma renin after blockade of the renin-system. Studies of conscious and anaesthetized, normal, adrenalectomized and spontaneously hypertensive rats.
    Bing J; Poulsen K
    Acta Pathol Microbiol Scand A; 1975 Sep; 83(5):454-66. PubMed ID: 170788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The immediate pressor response to saralasin in man: a test of angiotensin II receptor vacancy.
    Wallace JM; Case DB; Laragh JH; Keim HJ; Drayer JI; Sealey JE
    Circ Res; 1979 Jan; 44(1):38-44. PubMed ID: 214254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of the angiotensin antagonist saralasin on hemodynamics in hypertensive non-uraemic chronic renal disease.
    Brod J; Bahlmann J; Cachovan M; Hubrich W; Pretschner D
    Nephron; 1980; 25(4):167-72. PubMed ID: 6990284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Saralasin for renovascular or essential hypertension (author's transl)].
    Arlart I; Rosenthal J
    Dtsch Med Wochenschr; 1978 Nov; 103(45):1790-6. PubMed ID: 710289
    [No Abstract]   [Full Text] [Related]  

  • 30. Renin, sodium, and vasodepressor response to saralasin in renovascular and essential hypertension.
    Marks LS; Maxwell MH; Kaufman JJ
    Ann Intern Med; 1977 Aug; 87(2):176-82. PubMed ID: 889198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of renovascular hypertension: saralasin test versus renin determinations.
    Marks LS; Maxwell MH; Smith RB; Cahill PJ; Kaufman JJ
    J Urol; 1976 Oct; 116(4):406-9. PubMed ID: 1053323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the renin-angiotensin system in post-transplantation hypertension in patients with multiple kidneys.
    Linas SL; Miller PD; McDonald KM; Stables DP; Katz F; Weil R; Schrier RW
    N Engl J Med; 1978 Jun; 298(26):1440-4. PubMed ID: 349389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of saralasin to detect renovascular hypertension in childhood.
    Gillespie L; Ehrlich RM; Marks LS; Maxwell MH; Kaufman JJ
    Urology; 1980 Nov; 16(5):453-6. PubMed ID: 7003900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Renal tissue angiotensins during converting enzyme inhibition of angiotensin I in spontaneously hypertensive rat].
    Ingert C; Grima M; Michel B; Barthelmebs M; Imbs JL
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1135-41. PubMed ID: 9404423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin II blockade before and after marked sodium depletion in patients with hypertension.
    Van Hoogdalem P; Donker AJ; Leenen FH
    Clin Sci Mol Med; 1978 Jan; 54(1):75-83. PubMed ID: 620496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of saralasin in the recognition of angiotensinogenic hypertension.
    Streeten DH; Dalakos TG; Anderson GH
    Prog Biochem Pharmacol; 1976; 12():214-26. PubMed ID: 1019165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of an angiotensin blocker, sarcosyl1-alanyl8-angiotensin II (P113) on two kidney hypertension in the rat.
    Macdonald GJ; Boyd GW; Peart WS
    Clin Exp Pharmacol Physiol; 1975; Suppl 2():89-91. PubMed ID: 1183095
    [No Abstract]   [Full Text] [Related]  

  • 39. Angiotensin blockade in renovascular hypertension: a controlled, prospective study.
    Marks LS; Maxwell MH; Gross C; Waks U; Kaufman JJ
    Br J Urol; 1977 Jun; 49(3):181-8. PubMed ID: 334316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of continuous saralasin infusion to control hypertension.
    Ruley EJ; Bock GH; Smith D
    J Pediatr; 1982 Dec; 101(6):1013-7. PubMed ID: 7143155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.